GPBAR1 and NSAID gastroenteropathy

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 225-237

  Cipriani, Sabrina ^a   Mencarelli, Andrea ^a   Bruno, Angela ^a   Renga, Barbara ^a   Distrutti, Eleonora ^b   Santucci, Luca ^b   Baldelli, Franco ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

acetylsalicylic acid; bile acids; cystathionine liase; GPBAR1; hydrogen sulfide; NO; non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; BETULIC ACID; BILE ACID RECEPTOR; CIPROFLOXACIN; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GPBAR1 PROTEIN; HYDROGEN SULFIDE; MESSENGER RNA; NAPROXEN; NITRIC OXIDE; PROPARGYLGLYCINE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DISEASE PREDISPOSITION; ENZYME INHIBITION; GENE DELETION; GPBAR1 GENE; HUMAN; HUMAN CELL; INTESTINE MUCOSA LESION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SMALL INTESTINE; STOMACH; STOMACH MUCOSA LESION; WILD TYPE; ANIMAL; BILE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; GASTROINTESTINAL HEMORRHAGE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MALE; METABOLISM; PATHOLOGY; STOMACH MUCOSA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BILE; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MICE; NAPROXEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84872855413     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02128.x     Document Type: Article

References (42)

1. Abraham NS, (2011). Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations. Curr Opin Gastroenterol 27: 558-564.
2. th edition: G protein-coupled receptors. Br J Pharmacol 164: 5-113.
3. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817.
4. Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, et al. (2011). The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 6: e25637.
5. Costa NR, Paulo P, Caffrey T, Hollingsworth MA, Santos-Silva F, (2011). Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PLoS ONE 6: e26970.
6. Fiorucci S, (2001). NO-releasing NSAIDs are caspase inhibitors. Trends Immunol 22: 232-235.
7. 2S releasing NSAIDs. Inflamm Allergy Drug Targets 10: 133-140.
8. Fiorucci S, Distrutti E, de Lima OM, Romano M, Mencarelli A, Barbanti M, et al. (2003). Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 17: 1171-1173.
9. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, Orlandi S, et al. (2005). Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 129: 1210-1224.
10. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, Distrutti E, et al. (2007a). Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. JL. Br J Pharmacol 150: 996-1002.
11. 2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 39: 1043-1051.
12. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A, (2010). Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 49: 171-185.
13. Fiorucci S, Mencarelli A, Cipriani S, Renga B, Palladino G, Santucci L, et al. (2011). Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. Br J Pharmacol 164: 1929-1938.
14. Fitzgerald GA, (2004). Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711.
15. Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, et al. (2010). Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 53: 178-190.
16. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, et al. (2007). Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 25: 1211-1222.
17. Guang W, Ding J, Czinn SJ, Kim CK, Blanchard TG, Lillehoj EP, (2010). Muc1 cell surface mucin attenuates epithelial inflammation in response to a common mucosal pathogen. J Biol Chem 285: 20547-20557.
18. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, et al. (2010). Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 59: 170-180.
19. Katsuma S, Hirasawa A, Tsujimoto G, (2005). Bile acids promote glucagon like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophis Res Comm 329: 386-390.
20. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. (2003). A G protein-coupled receptor responsive to bile acids. J Biol Chem 278: 9435-9440.
21. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, et al. (2007). The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45: 695-704.
22. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, et al. (2008). Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 135: 1517-1525.
23. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. (2002). Identification of membrane-type receptor for bile acids (M-BAR). Biochem Bophys Res Commun 298: 714-719.
24. Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, et al. (2006). Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 191: 197-205.
25. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reportingexperiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Mino-Kenudson M, Tomita S, Lauwers GY, (2007). Mucin expression in reactive gastropathy: an immunohistochemical analysis. Arch Pathol Lab Med 131: 86-90.
27. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM, (2012). Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 165: 414-423.
28. Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B, et al. (2009). Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 52: 7958-7961.
29. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, et al. (2010). Expression and function of the bile acid receptor GP-BAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 22: 814-825.
30. Renga B, (2011). Hydrogen sulfide generation in mammals: the molecular biology of cystathionine-β- synthase (CBS) and cystathionine-γ-lyase (CSE). Inflamm Allergy Drug Targets 10: 85-91.
31. Reuter BK, Davies NM, Wallace JL, (1997). Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: 109-117.
32. Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, et al. (2011). A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 140: 892-902.
33. Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, et al. (2007). Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europea. Biochem Biophys Res Commun 362: 793-798.
34. Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, et al. (2006). Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J 398: 423-430.
35. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S, (2009). The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183: 6251-6261.
36. Wallace JL, (2007). Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci 28: 501-505.
37. Wallace JL, (2008). Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88: 1547-1565.
38. Wallace JL, Caliendo G, Santagada V, Cirino G, (2010). Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 159: 1236-1246.
39. Wang YD, Chen WD, Yu D, Forman BM, Huang W, (2011). The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 54: 1421-1432.
40. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. (2006). Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489.
41. Wolfe MM, Lichtenstein DR, Singh G, (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.
42. Zhou Y, Dial EJ, Doyen R, Lichtenberger LM, (2010). Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 298: G722-G731.